Chinook Therapeutics Stock (NASDAQ:KDNY)
Previous Close
$40.30
52W Range
$18.34 - $40.51
50D Avg
$36.70
200D Avg
$26.37
Market Cap
$2.71B
Avg Vol (3M)
$2.04M
Beta
0.67
Div Yield
-
KDNY Company Profile
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
KDNY Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DICE | DICE Therapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| NUVL | Nuvalent, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| KALV | KalVista Pharmaceuticals, Inc. |
| VRDN | Viridian Therapeutics, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| CERE | Cerevel Therapeutics Holdings, Inc. |
| RNA | Avidity Biosciences, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ASND | Ascendis Pharma A/S |
| ACLX | Arcellx, Inc. |
| GPCR | Structure Therapeutics Inc. |
| PCVX | Vaxcyte, Inc. |
| SWTX | SpringWorks Therapeutics, Inc. |
| KURA | Kura Oncology, Inc. |